$4.33
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The company is headquartered in Boca Raton, Florida and currently employs 3 full-time employees. The company went IPO on 2007-09-21. Its product consists of Voyager Eagle, Voyager Falcon, and Voyager Hawk. The company also continues to advance its life sciences portfolio through LIXTE Biotechnology and Liora Technologies, including the development of novel oncology therapeutics and medical technologies. The firm is focused on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100. LB-100 is being tested in clinical trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. Liora Technologies provides Linac for Image Guided Hadron Therapy (LiGHT) system technology, installation support, ongoing maintenance, software upgrades, and clinical/technical training.
Country

US

CEO

Mr. Geordan Pursglove

IPO date

2007

Employees

3

ISIN

US5393193017

Key stats

Open

$4.30

Volume

131.89K

Market cap

$67.79M

Prev. close

$4.20

Impl / hst vl

-

Open interest

$0.00

$4.24

Day’s Range

$4.44

$3.12

52W Range

$7.70

Valuation

33
Valuation score
Overvalued
P/E
-
P/S
-
P/B
-
Current ratio
2.78
Debt / Equity
-
ROE
-124.69%
Gross margin
-
Income growth
-24.23%
FCF growth
68.34

Analysts estimates

Earnings

Q1 ‘26 revenue
$0.00
Q1 ‘26 net income
-$1.94M
Revenue
Net income
Previous EPS
-
Estimate EPS
$0.00
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply